This page shows what was measured, who it was measured in, and what that does not settle.
What Enzalutamide does in the body
The treatment of patients
From the FDA-approved label: Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N‑desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro , and decreased tumor volume in a mouse prostate cancer xenograft model.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 93T0T9GKNU · read 2026-08-29
Its recorded molecular formula is C21H16F4N4O2S, weighing 464.44.
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 100 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Protein
A protein is a folded chain your body builds to do a specific job.
A picture of it, and where the picture fails
A protein is like a tool bent into one shape for one task.
Where that stops being true. A tool keeps its shape. A protein can change shape and stop working.
What people get wrong. Protein in food and a protein in the body are related but not the same thing.
A polymer of amino acids folded into a defined structure that determines its function.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Overall survival
✗ The study did not show it
Who was studied
NCT00268476
How many people
11992
Study design
Phase 2/Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
✗ The study did not show it
Who was studied
NCT07620574
How many people
5000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Overall Survival (OS)
✗ The study did not show it
Who was studied
NCT06320067
How many people
3360
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Radiographic Progression-Free Survival (rPFS)
✗ The study did not show it
Who was studied
NCT06120491
How many people
1898
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Overall Survival
✗ The study did not show it
Who was studied
NCT01212991
How many people
1717
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
overall survival
✗ The study did not show it
Who was studied
NCT05974774
How many people
1600
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.9 registered measures of this kind. 5 written-up studies measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
□A number that stands in for healthNo evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.No registered study measures this.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
No registered study measured anything of this kind.
Meaningful
Things that change how a life goes, not only a number.
overall survival
radiographic progression free survival
progression free survival
metastasis free survival
psa progression free survival
two year progression free survival
radiological progression free survival
part b progression free survival
overall survival time
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (31)
dose limiting toxicities
maximum tolerated dose of ipatasertib
recommended phase ii dose of ipatasertib
adverse events
pathologic complete response rate
who discontinued study drug due to an adverse event
dose escalation phase percentage of dose limiting toxicity
treatment emergent serious adverse events
who require dose reductions due to adverse events
time to progression
tumor growth rate
pathologic stage less than or equal to ypt2n0
overall response rate
partial response
n cadherin and vimentin expression
bone scan response rate
bone scan lesion area
clinical benefit rate
prostate specific antigen response rate
serious and non serious adverse events
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 5.8 days
Read from the label, which states: “The mean terminal half-life (t 1/2 ) for enzalutamide after a single oral dose is 5.8 days (2.8 to 10.2 days).”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with: • castration-resistant prostate…
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of XTANDI in pediatric patients have not been established.”
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-30
On older people, the label states: “Of 5112 patients who received XTANDI in eight randomized, controlled clinical trials, 78% were 65 and over, while 33% were 75 and over.”
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary The safety and efficacy of XTANDI have not been established in females.”
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-30
On people with reduced liver function, the label states: “No dosage modification is recommended for patients with mild, moderate, or severe hepatic impairment [see Clinical Pharmacology ( 12.3 )].”
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-30
On people with reduced kidney function, the label states: “No dosage modification is recommended for patients with mild to moderate renal impairment (creatinine clearance [CLcr] ≥ 30 mL/min).”
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Sold as capsule, tablet, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Enzalutamide appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 5915 reaction mentions were counted. One report can name several reactions.
prostatic specific antigen increased — 751 reaction mentions
asthenia — 589 reaction mentions
decreased appetite — 502 reaction mentions
dysphagia — 359 reaction mentions
back pain — 300 reaction mentions
hot flush — 298 reaction mentions
prostate cancer — 145 reaction mentions
metastases to bone — 104 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
26 products list this as an active ingredient in the United States drug directory. 26 of them contain it and nothing else.
FDA National Drug Code directory · 0469-0625 · read 2026-08-29
They are sold as capsule, powder and tablet, taken oral.
FDA National Drug Code directory · 0469-0625 · read 2026-08-29
The regulator's established pharmacologic class for it is androgen receptor antagonists [moa], androgen receptor inhibitor [epc] and cytochrome p450 2c19 inducers [moa].
FDA National Drug Code directory · 0469-0625 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-29
Xtandi is oral at 3 DOSAGE FORMS AND STRENGTHS XTANDI 40 mg capsules are white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ., recorded as fda label in effect 2026-07-28 in the United States.
US prescribing information · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Enzalutamide studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Enzalutamide are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
FDA substance identifier (UNII)
93T0T9GKNU
RxNorm concept
1307303
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S3.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
9 approved applications cover products containing this substance. The earliest was NDA203415, approved 20120831 to ASTELLAS.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q2
What did Enzalutamide's largest trial (500000 people) and its longest (26 years) measure?
500000 people in Enzalutamide's largest registered study, 26 years in its longest registered window, measuring Overall Survival Time. ClinicalTrials.gov · 2026-09-01
175 phase2, 93 phase1, 49 phase3, 29 na or unstated, 11 phase4, 2 na, 1 early phase1; NCT02023463; 2040-01-01; no ageing endpoint recorded. Last human test completed 2026, NCT05901649.
Interpretation These counts include studies where Enzalutamide was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
175
phase1
93
phase3
49
na or unstated
29
phase4
11
na
2
2 more recorded rows
early phase1
1
Last recorded human testNCT05901649
2026-06-16
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Enzalutamide shown lifespan?
"A business decision was made to not initiate this study."; 47 of 321 registered studies
Show the evidence
Trial
NCT01663415
withdrawn; "A business decision was made to not initiate this study."
NCT01885949
terminated; "Slow accrual"
NCT02159690
withdrawn; "loss of funding"
NCT02379390
terminated; "Unsatisfactory patient accrual"
NCT02380313
withdrawn; "Study cancelled: Withdrawn before enrollment of any participants"
NCT02441517
terminated; "The study is closed early due to lck of enrollment."
14 further recorded trials
NCT02457910
terminated; "Interim analysis - toxicity"
NCT02489123
terminated; "Accrual goal not met"
NCT02491411
terminated; "The study is terminated due to lower enrollment"
NCT02500901
terminated; "Suspended by funder"
NCT02508636
terminated; "Low Accrual"
NCT02555189
terminated; "Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib to standard of care enzalutamide did not demonstrate benefit, an all active subjects were removed from the study."
NCT02605863
terminated; "Low enrollment, sponsor withdrew support for study"
NCT02640534
terminated; "The decision is based on the fact that with the current follow up of around 10 years, the relevant secondary endpoints can adequately be addressed according to protocol. The addition of follow up data will not significantly impact these…"
NCT02758132
terminated; "Low accruals"
NCT02885649
terminated; "Funding unavailable"
NCT02929576
withdrawn; "Further understanding about the role of androgen signaling in TNBC was required"
NCT03150056
terminated; "This study has been terminated due to meeting protocol defined futility."
NCT03177187
terminated; "Discontinuation of production of IMP"
NCT03300505
terminated; "Cancelled by the sponsor"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Enzalutamide used Enzalutamide 160mg daily (oral) — over how long?
5 recorded entries; human; oral, capsule; also "Enzalutamide 160mg daily (oral)", "Enzalutamide 160 mg", "Enzalutamide 40 MG"
Show the evidence
human
NCT02254785
oral; Enzalutamide 160mg daily (oral)
NCT02861573
Enzalutamide 160 mg
NCT03177187
Enzalutamide 40 MG
NCT06126731
Enzalutamide 40mg
NCT07683013
capsule; Enzalutamide 40 mg capsule
recorded 2026-09-01 · last checked 2026-09-04
Q6
Enzalutamide's half-life is 5.8 days — which schedules were studied?
5.8 days, the half-life Enzalutamide's label states. openfda-label · b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf · 2026-08-30
Show the evidence
half life
5.8 days; The mean terminal half-life (t 1/2 ) for enzalutamide after a single oral dose is 5.8 days (2.8 to 10.2 days).
metabolism
Elimination Enzalutamide is primarily eliminated by hepatic metabolism.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which of acute treatment related toxicity, adverse events and bone scan lesion area did Enzalutamide's trials measure?
acute treatment related toxicity, adverse events and bone scan lesion area lead 40 outcome terms across Enzalutamide's trials. ClinicalTrials.gov · 2026-09-01
Interpretation maximum tolerated dose of ipatasertib, recommended phase ii dose of ipatasertib, adverse events, pathologic complete response rate, who discontinued study drug due to an adverse event and dose escalation phase percentage of dose limiting toxicity follow.
Show the evidence
overall survival
1
radiographic progression free survival
1
dose limiting toxicities
1
maximum tolerated dose of ipatasertib
1
recommended phase ii dose of ipatasertib
1
adverse events
1
14 more recorded rows
pathologic complete response rate
1
who discontinued study drug due to an adverse event
1
dose escalation phase percentage of dose limiting toxicity
1
treatment emergent serious adverse events
1
who require dose reductions due to adverse events
1
progression free survival
1
time to progression
1
tumor growth rate
1
pathologic stage less than or equal to ypt2n0
1
overall response rate
1
partial response
1
n cadherin and vimentin expression
1
metastasis free survival
1
psa progression free survival
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Enzalutamide's 108 ongoing trials reports first?
Overall survival; N-cadherin and vimentin expression; latest 2041-08
Show the evidence
Trial
NCT00268476
"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy"; n 11992; "Overall survival"; 2030-12
NCT01990196
"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer"; n 45; "N-cadherin and vimentin expression"; 2026-09-30
NCT02023463
"Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer"; n 25; "Acute toxicities, monitored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 criteria"; 2040-01-01
NCT02194842
"Phase III Radium 223 mCRPC-PEACE III"; n 446; "radiological progression-free survival"; 2028-12
NCT02312557
"Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide"; n 58; "PSA Response, Defined by a PSA Decrease of at Least 50% Confirmed by a Second Measurement at Least 3 Weeks Later"; 2026-10-31
NCT02319837
"Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)"; n 1068; "Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide"; 2026-09-19
14 further recorded trials
NCT02446405
"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer"; n 1125; "Overall Survival Time"; 2027-06-30
NCT02446444
"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer"; n 802; "Metastasis-free survival"; 2026-06
NCT02452008
"Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer"; n 60; "Progression free survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2) using RECIST 1.1 criteria."; 2026-12
NCT02522715
"Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer"; n 37; "Percentage of Participants With Dose Limiting ToxicitiesGgraded by National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (Phase I)"; 2027-01-01
NCT02685397
"Management of Castration-Resistant Prostate Cancer with Oligometastases"; n 102; "Radiographic Progression-free Survival"; 2041-08
NCT02749903
"Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers"; n 46; "Best Overall Response Rate"; 2028-07-05
NCT02750358
"Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer"; n 50; "The treatment discontinuation rate of enzalutamide in the adherent population"; 2027-05
NCT02861573
"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)"; n 1200; "Percentage of Participants With a Decrease of ≥50% in Prostatic Specific Antigen (PSA)"; 2028-07-24
NCT02955394
"Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer"; n 61; "Number of Patients With a PEPI Score Equal to Zero at Post Treatment"; 2027-02
NCT02960022
"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study"; n 900; "Number of participants with adverse events"; 2029-07-31
NCT03016741
"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer"; n 100; "Cognitive function defined by overall Cogstate score and Cogstate module scores for each domain"; 2029-08
NCT03246347
"A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer"; n 40; "52-week PSA Complete Response (CR) Rate"; 2028-03
NCT03344211
"Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer"; n 30; "Changes in prostate cancer bone involvement"; 2027-12-31
NCT03460977
"A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma"; n 453; "Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)"; 2029-07-07
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Enzalutamide could settle lifespan?
NCT02446444 measures Metastasis-free survival, reading out 2026-06.
40 open trials; n 802; "Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer"
Show the evidence
Trial
NCT02446444
"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer"; n 802; "Metastasis-free survival"; 2026-06
NCT02319837
"Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)"; n 1068; "Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide"; 2026-09-19
NCT04446117
"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC"; n 575; "Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)"; 2026-10-16
NCT02452008
"Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer"; n 60; "Progression free survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide and LY2157299 (Arm 1) versus enzalutamide alone (Arm 2) using RECIST 1.1 criteria."; 2026-12
NCT03903835
"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer"; n 750; "Progression free survival (PFS) in mCRPC"; 2026-12
NCT04015622
"PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA"; n 100; "Progression free survival (PFS)"; 2026-12-01
14 further recorded trials
NCT04419402
"Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer"; n 162; "Prostate Specific Antigen (PSA) Progression-Free Survival"; 2026-12-01
NCT05457257
"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations"; n 43; "Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)"; 2026-12-31
NCT04986423
"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer"; n 200; "Cohort A: Radiographic progression-free survival (rPFS) by BICR"; 2027-06
NCT02446405
"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer"; n 1125; "Overall Survival Time"; 2027-06-30
NCT04455750
"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy"; n 61; "Radiographic progression-free survival (rPFS)"; 2027-09
NCT06099769
"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer"; n 201; "progression-free survival (PFS)"; 2027-10
NCT04647526
"Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment"; n 455; "Randomization Phase: Radiographic Progression-Free Survival (rPFS)"; 2028-03
NCT06652607
"PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer"; n 152; "To evaluate the survival based on the PSA response at six months from the beginning of ARPI in patients with mCSPC."; 2028-04-30
NCT04363164
"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression"; n 150; "Clinical or Radiographic Progression free survival"; 2028-07
NCT05189457
"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer"; n 32; "Overall Survival"; 2028-07
NCT06551324
"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1)."; n 600; "Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)"; 2028-10-29
NCT06629779
"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer."; n 900; "Radiographic Progression Free Survival (rPFS)"; 2028-11-30
NCT02194842
"Phase III Radium 223 mCRPC-PEACE III"; n 446; "radiological progression-free survival"; 2028-12
NCT06473259
"Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients"; n 3000; "progression free survival"; 2028-12
Q10
Which 56 trials of Enzalutamide posted no result?
Posted no result
56 of 56 completed trials
Registrations
NCT01911715, NCT01913379, NCT01901133, NCT01911728, NCT01911741 and NCT02138799, and 50 more
Completion dates
oldest 2011-07; newest 2024-08-30
Show the evidence
Trial
NCT01911715
2011-07
NCT01913379
2011-12
NCT01901133
2012-01
NCT01911728
2012-02-21
NCT01911741
2013-03
NCT02138799
2013-09
14 further recorded trials
NCT01902251
2013-10
NCT02225093
2014-02-03
NCT02138162
2014-03
NCT01284920
2014-07-02
NCT02676986
2016-12-31
NCT03297385
2017-04-01
NCT02124668
2017-05-25
NCT02532114
2017-11-30
NCT03328364
2017-12-24
NCT02353715
2018-11-14
NCT02669771
2018-11-30
NCT02507570
2019-01-18
NCT02346578
2019-01-22
NCT02495974
2019-02-08
Q11
At the median, Enzalutamide's trials enrolled 66 people — anything larger?
Median enrolment
66
Largest enrolment
500000
Registered trials counted
320
Q12
What do 5915 spontaneous reports say about Enzalutamide — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Enzalutamide appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 5915 reaction mentions were counted: fatigue 1436; malignant neoplasm progression 1431; prostatic specific antigen increased 751; asthenia 589. open-targets-adr · CHEMBL1082407 · 2026-06-24
Show the evidence
fatigue
1436
malignant neoplasm progression
1431
prostatic specific antigen increased
751
asthenia
589
decreased appetite
502
dysphagia
359
4 more recorded rows
back pain
300
hot flush
298
prostate cancer
145
metastases to bone
104
recorded 2026-06-24 · last checked 2026-09-04
Q13
Enzalutamide and CYP2C8, CYP3A4 and BCRP: shared by which compounds?
CYP2C8, CYP3A4 and BCRP appear in Enzalutamide's recorded interaction sentences, 14 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2pharmacokinetics
No clinically meaningful changes in exposure of pioglitazone (a sensitive CYP2C8 substrate), caffeine (a sensitive CYP1A2 substrate), dextromethorphan (a sensitive CYP2D6 substrate), or rosuvastatin (a BCRP substrate) were observed following coadministration with XTANDI.
CYP2B6pharmacokinetics
In Vitro Studies Cytochrome P450 (CYP) Enzymes : Enzalutamide induces CYP2B6 at clinically achievable concentrations.
CYP2C19pharmacokinetics
Coadministration of XTANDI 160 mg orally once daily with omeprazole (a sensitive CYP2C19 substrate) decreased omeprazole AUC by 72% and C max by 62%.
CYP2C8
pharmacokinetics
Metabolism Enzalutamide is metabolized by CYP2C8 and CYP3A4.
pharmacokinetics
CYP2C8 is primarily responsible for the formation of the active metabolite (N-desmethyl enzalutamide).
pharmacokinetics
Drug Interaction Studies Clinical Studies Effect of CYP2C8 Inhibitors on XTANDI : The coadministration of XTANDI 160 mg with gemfibrozil (strong CYP2C8 inhibitor) increased the AUC of enzalutamide plus N-desmethyl enzalutamide by 2.2-fold with minimal effect on C max .
pharmacokinetics
Effect of CYP3A4 and CYP2C8 Inducers on XTANDI : The coadministration of XTANDI 160 mg after multiple oral doses of rifampin (strong CYP3A4 and moderate CYP2C8 inducer) decreased the AUC of enzalutamide plus N-desmethyl enzalutamide by 37% with no effect on C max .
pharmacokinetics
No clinically meaningful changes in exposure of pioglitazone (a sensitive CYP2C8 substrate), caffeine (a sensitive CYP1A2 substrate), dextromethorphan (a sensitive CYP2D6 substrate), or rosuvastatin (a BCRP substrate) were observed following coadministration with XTANDI.
CYP2C9pharmacokinetics
Coadministration of XTANDI 160 mg orally once daily with warfarin (a sensitive CYP2C9 substrate) decreased S‑warfarin AUC by 56% and C max by 17%.
CYP2D6pharmacokinetics
No clinically meaningful changes in exposure of pioglitazone (a sensitive CYP2C8 substrate), caffeine (a sensitive CYP1A2 substrate), dextromethorphan (a sensitive CYP2D6 substrate), or rosuvastatin (a BCRP substrate) were observed following coadministration with XTANDI.
CYP3A4
pharmacokinetics
Metabolism Enzalutamide is metabolized by CYP2C8 and CYP3A4.
pharmacokinetics
Effect of CYP3A4 and CYP2C8 Inducers on XTANDI : The coadministration of XTANDI 160 mg after multiple oral doses of rifampin (strong CYP3A4 and moderate CYP2C8 inducer) decreased the AUC of enzalutamide plus N-desmethyl enzalutamide by 37% with no effect on C max .
pharmacokinetics
Effect of CYP3A4 Inhibitors on XTANDI : The coadministration of XTANDI 160 mg after multiple oral doses of itraconazole (strong CYP3A4 inhibitor) increased the AUC of enzalutamide plus N-desmethyl enzalutamide by 1.3-fold with no effect on C max .
pharmacokinetics
Effect of XTANDI on Other Drugs: The coadministration of XTANDI 160 mg orally once daily with midazolam (a sensitive CYP3A4 substrate) decreased midazolam AUC by 86% and C max by 77%.
recorded 2026-08-30 · last checked 2026-09-04
Q14
Was Enzalutamide studied with exercise?
exercise is named in Enzalutamide's label sentences: "We randomized 26 patients to 16 weeks of supervised exercise (aerobic and resistance), starting 4 weeks before initiation of ADT and enzalutamide, or usual care." openfda-label+europepmc · 2026-08-30
1 recorded statement; exercise
Show the evidence
exercise
We randomized 26 patients to 16 weeks of supervised exercise (aerobic and resistance), starting 4 weeks before initiation of ADT and enzalutamide, or usual care.
recorded 2026-08-30 · last checked 2026-09-04
Q15
What is recorded about Enzalutamide and AMPK?
"We revealed that CAMK1D interacts with and phosphorylates AMPK at Thr172, which in turn activates PINK1 to modulate mitophagy, ultimately supporting the expansion of PCSCs under enzalutamide treatment." — where Enzalutamide and AMPK appear together. Europe PMC · pathway abstract search · 2026-01-28
"We revealed that CAMK1D interacts with and phosphorylates AMPK at Thr172, which in turn activates PINK1 to modulate mitophagy, ultimately supporting the expansion of PCSCs under enzalutamide treatment."
PMID 41419457
"In a mouse orthotopic PCa model, targeting the CAMK1D/AMPK pathway with the siCAM/HLNP nanoformulation suppresses tumor growth by depleting the PCSCs population, achieving a synergistic effect with enzalutamide therapy."
autophagyPMID 41605902
"Furthermore, inhibition of autophagy or GNG4 knockdown significantly increased the antitumor efficacy of enzalutamide both in vitro and in vivo."
NAD+PMID 41366824
"NAPRT-deficiency (NAPRT-low) can be a novel vulnerability associated with the AR-low/EMT-high phenotype and thus can be targeted by NAD+ inhibitors to improve enzalutamide efficacy."
mTORPMID 42327601
"This review comprehensively examines the multifaceted mechanisms underlying enzalutamide resistance, including AR amplification, point mutations, splice variants such as AR-V7, and the activation of bypass signaling pathways, including glucocorticoid receptor signaling, PI3K/Akt/mTOR, and Wnt signaling."
autophagyPMID 39531508
"ATC-324 was designed to comprise enzalutamide, an AR inhibitor, as a target-binding ligand and YT 6-2, a ligand of the autophagy receptor p62/SQSTM1, as an autophagy-targeting ligand."
NAD+
"Indeed, treating AR low/- cells with NAD+ synthesis inhibitors, FK866 and OT-82, significantly inhibited the survival and proliferation of AR low/- cells, thus suggesting a possible novel therapeutic option for ADT and enzalutamide resistant PCa."
autophagyPMID 38859837
"Transcriptomic analysis revealed the essential role of TPT1-AS1 in synaptogenesis and autophagy activation in neuroendocrine differentiated PCA cells induced by IL-6 and enzalutamide treatment."
mTOR
PMID 37228586
"This follow-up screen provided validation of inhibitors of JAK/STAT and PI3K/mTOR as therapeutic vulnerabilities for both Snail+ and enzalutamide-resistant prostate cancer."
PMID 35811549
"Activation of AR signaling by dihydrotestosterone (DHT) downregulated miR-99b expression and promoted cell PCa cell growth/survival, whereas inactivation of mTOR by rapamycin or AR by enzalutamide decreased miR-99b mediated PCa cell growth."
recorded 2026-01-28 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.